UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1218-8
Program Prior Authorization/Notification
Medication Emflaza® (deflazacort)*
P&T Approval Date 5/2017, 10/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023,
10/2024
Effective Date 1/1/2025
1. Background:
Emflaza (deflazacort)* is a corticosteroid indicated for the treatment of Duchenne muscular
dystrophy (DMD) in patients 2 years of age and older.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Emflaza* will be approved based on the following criterion:
a. Diagnosis of Duchenne muscular dystrophy
Authorization will be issued for 12 months
B. Reauthorization
1. Emflaza* will be approved based on the following criterion:
a. Documentation of positive clinical response to Emflaza therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Emflaza is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer
to plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits, Medical Necessity and/or Step Therapy may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Emflaza [package insert]. Warren, NJ: PTC Therapeutics, Inc.; May 2024.
Program Prior Authorization/Notification - Emflaza (deflazacort)
Change Control
5/2017 New program.
10/2018 Annual review. No changes to criteria. Updated reference.
10/2019 Annual review. Updated background updating indication in patients 2
years and older. Updated reference.
10/2020 Annual review. No change to clinical criteria.
10/2021 Annual review with no change to clinical criteria. Reference updated.
10/2022 Annual review with no change to clinical criteria. Added state mandate
footnote.
10/2023 Annual review with no changes to coverage criteria.
10/2024 Annual review with no changes to coverage criteria. Added exclusion
footnote and updated reference.
© 2024 UnitedHealthcare Services, Inc.
2
© 2024 UnitedHealthcare Services, Inc.
3